HK1246824A1 - 应用人脂肪衍生的干细胞增殖血清来源的丙肝病毒及其用途 - Google Patents

应用人脂肪衍生的干细胞增殖血清来源的丙肝病毒及其用途 Download PDF

Info

Publication number
HK1246824A1
HK1246824A1 HK18106252.0A HK18106252A HK1246824A1 HK 1246824 A1 HK1246824 A1 HK 1246824A1 HK 18106252 A HK18106252 A HK 18106252A HK 1246824 A1 HK1246824 A1 HK 1246824A1
Authority
HK
Hong Kong
Prior art keywords
hadsc
viral
replication
virus
hcv
Prior art date
Application number
HK18106252.0A
Other languages
English (en)
Chinese (zh)
Inventor
Chen-Lung Lin
Original Assignee
Frontier Bio-Drug Development Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frontier Bio-Drug Development Limited filed Critical Frontier Bio-Drug Development Limited
Publication of HK1246824A1 publication Critical patent/HK1246824A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/70—Non-animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/186—Hepatitis C; Hepatitis NANB

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK18106252.0A 2015-01-07 2015-01-07 应用人脂肪衍生的干细胞增殖血清来源的丙肝病毒及其用途 HK1246824A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2015/070243 WO2016109947A1 (en) 2015-01-07 2015-01-07 Employing human adipose-derived stem cells to propagate serum-derived hepatitis c virus and use thereof

Publications (1)

Publication Number Publication Date
HK1246824A1 true HK1246824A1 (zh) 2018-09-14

Family

ID=56355408

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18106252.0A HK1246824A1 (zh) 2015-01-07 2015-01-07 应用人脂肪衍生的干细胞增殖血清来源的丙肝病毒及其用途

Country Status (10)

Country Link
US (1) US10273461B2 (enExample)
EP (1) EP3242932A4 (enExample)
JP (1) JP6670322B2 (enExample)
KR (1) KR20170101998A (enExample)
CN (1) CN107208060B (enExample)
AU (1) AU2015376561A1 (enExample)
CA (1) CA2973119A1 (enExample)
HK (1) HK1246824A1 (enExample)
TW (1) TWI616528B (enExample)
WO (1) WO2016109947A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL272145A (en) * 2020-01-20 2021-07-29 Stem Cell Medicine Ltd Cosmetic preparations with protein concentrate from a conditioned growth medium of stem cells from adipose tissue
IL278473A (en) 2020-11-03 2022-06-01 Yeda Res & Dev Methods for diagnosing and determining treatment in multiple myeloma
CN114686517A (zh) * 2020-12-25 2022-07-01 中国医学科学院病原生物学研究所 一种hcv四受体转基因合并stat1敲除小鼠的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786207A (en) 1997-05-28 1998-07-28 University Of Pittsburgh Tissue dissociating system and method
CN1166773C (zh) 1997-12-02 2004-09-15 泽恩比奥公司 分离的人脂肪组织衍生的基质细胞
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
US20050076396A1 (en) 1999-03-10 2005-04-07 Katz Adam J. Adipose-derived stem cells and lattices
JP2009153383A (ja) * 2006-04-03 2009-07-16 Eci Inc 成熟肝細胞様細胞の製造方法
KR101224504B1 (ko) * 2010-10-01 2013-01-22 가톨릭대학교 산학협력단 크립토탄신온의 신규 용도
GB201119335D0 (en) * 2011-11-09 2011-12-21 Univ Leuven Kath Hepatitis virus infectable stem cells
US20140179775A1 (en) * 2012-02-29 2014-06-26 Mead Johnson Nutrition Company Neurogenesis screening method and uses thereof
US9402710B2 (en) * 2012-07-16 2016-08-02 The Board Of Trustees For The Leland Stanford Junior University Macroporous 3-D scaffolds for tissue engineering

Also Published As

Publication number Publication date
EP3242932A4 (en) 2018-05-30
EP3242932A1 (en) 2017-11-15
CA2973119A1 (en) 2016-07-14
AU2015376561A1 (en) 2017-07-27
JP2018501820A (ja) 2018-01-25
KR20170101998A (ko) 2017-09-06
US10273461B2 (en) 2019-04-30
JP6670322B2 (ja) 2020-03-18
WO2016109947A1 (en) 2016-07-14
TWI616528B (zh) 2018-03-01
CN107208060A (zh) 2017-09-26
TW201625786A (zh) 2016-07-16
CN107208060B (zh) 2021-06-18
US20180023058A1 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
Jensen et al. Highly efficient JFH1-based cell-culture system for hepatitis C virus genotype 5a: failure of homologous neutralizing-antibody treatment to control infection
Pan et al. Hepatic cell-to-cell transmission of small silencing RNA can extend the therapeutic reach of RNA interference (RNAi)
Yoshida et al. Use of human hepatocyte-like cells derived from induced pluripotent stem cells as a model for hepatocytes in hepatitis C virus infection
PH12013501683A1 (en) Yeast-based therapeutic for chronic hepatitis b infection
WO2012140127A3 (en) Method for priming of t cells
MX2014014683A (es) Peptidos derivados de proteinas virales para usarse como inmunogenos y reactivos de dosificacion.
Wang et al. Stem cell‐derived hepatocyte‐like cells as model for viral hepatitis research
HK1246824A1 (zh) 应用人脂肪衍生的干细胞增殖血清来源的丙肝病毒及其用途
NZ599677A (en) Production of ifn-lambda by conventional dendritic cells and uses thereof
Wang Scotomas in molecular virology and epidemiology of hepatitis C virus
Douam et al. Specialization of hepatitis C virus envelope glycoproteins for B lymphocytes in chronically infected patients
GB201119335D0 (en) Hepatitis virus infectable stem cells
Kushch et al. Exosomes in the life cycle of viruses and the pathogenesis of viral infections
GB201008123D0 (en) Novel compounds
Ebrahimi et al. A State‐of‐the‐Art Review on the Recent Advances in Exosomes in Oncogenic Virus
Fukuhara et al. Intracellular delivery of serum-derived hepatitis C virus
Hossain et al. Expression profile of SARS-COV-2 entry receptor ACE2 in the hepatocellular carcinoma and its impact on Covid-19 patients
Watashi HBV slow maturation process leads to infection
Chen et al. Different responses of two highly permissive cell lines upon HCV infection
WO2007046962A3 (en) Cell lines harboring hepatitis virus and methods for using thereof
Li et al. Progress in studies on HCV receptor of Tupaia as a potential hepatitis C animal model
Kriss et al. Human liver sinusoidal endothelial cell-derived exo-somes augment intrinsic anti-viral pathways in HCV-infected hepatocytes: Differential Effects of Type I vs Type III Interferons: 1775
Cho The Applications of Hepatitis C Virus (HCV) Replication System in Developing Anti-HCV Reagents
Fan et al. Effects of hepatitis C virus gene NS2 on the expressions of Bcl-2 and Bax in HepG2 cells
Lyon Specialization of hepatitis C virus envelope glycoproteins for B-lymphocytes in chronically infected patients 2